Telehealth platform Wisp launches a new healthy aging category, betting that women’s longevity care is the next major gap and opportunity.
For years, Wisp has been best known for meeting women where much of traditional healthcare has often fallen short: online, discreetly and without the friction that so often turns basic care into an ordeal.
Now, the New York-based company is taking that model somewhere more ambitious. Wisp, which describes itself as the largest pure-play women’s telehealth provider in the US, has launched a new Longevity and Healthy Aging category, a move that pushes it beyond reproductive and sexual health and into longevity, one of the most crowded, confusing and increasingly lucrative corners of modern medicine [1].
At first glance, the new offering may look familiar to anyone who has spent time around the wellness internet. The initial treatments include NAD+, glutathione and low-dose naltrexone (LDN), names that have circulated heavily in biohacking circles and premium wellness clinics.
Wisp is trying to tell a different story. Rather than packaging longevity as a playground for self-optimizers chasing the next performance edge, it is positioning these therapies as part of clinician-guided care for women navigating the slower, messier realities of aging. Fatigue that doesn’t quite go away. Brain fog that starts to feel less occasional. Hormonal transitions that disrupt sleep, mood and energy. The quiet frustration of being told to “wait and see.”
It’s longevity, but translated into real life. For all its big promises, longevity still has an accessibility problem, so what Wisp is doing is very important.
Too much of the category remains wrapped in jargon, expensive protocols and the kind of language that makes everyday patients feel like they need a biochemistry degree just to understand the pitch. Wisp’s move suggests a simpler proposition: take some of the science people are already hearing about, strip away the cultish gloss and build it into a care model that feels less like a trend and more like a health service.
In practical terms, the company says the therapies are intended to support areas such as energy production, cellular repair and immune function. This is best understood less as “antiaging magic” and more as maintenance. Think of it as trying to keep the body’s internal systems running smoothly for longer.
Patients accessing the new category will receive asynchronous consultations, clinician oversight and ongoing treatment adjustments through Wisp’s digital platform. That may sound procedural, but it is central to the business model. This is not simply about selling a nasal spray or an injection online; it is about turning longevity into a repeat relationship rather than a one-off purchase.
Wisp’s expansion points to a broader shift in how longevity is being commercialized. The first wave of the sector was often built around aspiration: premium supplements, advanced testing, concierge clinics and a biohacking culture that skewed male, affluent and performance-obsessed. The next phase may be less glamorous but far more scalable – integrating healthy aging into mainstream digital care. And women may be one of the clearest places to start.
According to a Wisp survey of nearly 2,000 women in the US, 75% said they already prioritize long-term health in their daily choices. Yet nearly half said they are unsure which interventions actually work for women’s bodies [2]. Even more telling, 92% believe telehealth is important for healthy aging, but only 11% feel current digital tools give them a sense of control over their long-term health.
That gap – between desire and confidence, between access and actual trust – is where Wisp is planting its flag.
According to Monica Cepak, the CEO of Wisp, women are being left behind as the telehealth market for treatments such as NAD+ and glutathione becomes more expensive and fragmented.
“Women are navigating complex hormonal transitions and immune issues that don’t fit into a standard biohacking framework. We’re translating complex science into clear, clinician-guided plans that support women long before something escalates,” she said.
Women’s longevity is becoming harder to ignore
If longevity has often been marketed as universal, the reality is that much of the industry has not been built that way.
Women experience aging through different biological and social pressures, especially around perimenopause and menopause, where symptoms like chronic fatigue, cognitive disruption and immune-related issues can be dismissed, normalized or treated in isolation rather than as part of a bigger healthspan conversation.
That is why Wisp’s move feels timely. It reflects a growing recognition that the future of longevity will not be won only by whoever promises the longest life, but by whoever makes longer, healthier living feel believable and usable for ordinary people.
“We are helping women take control of their healthspan, not just their lifespan,” said Dr Shannon Chatham, Medical Director at Wisp. “This isn’t about chasing trends, it’s about providing evidence-based, sustainable care that meets the real needs of women as they age.”
The bigger longevity question
There is, of course, a note of caution here. Longevity remains a field where marketing often runs ahead of evidence, and any company entering the space will have to prove it can balance consumer demand with clinical rigor.
Still, Wisp’s launch captures something important about where the sector is heading. Longevity is no longer just a luxury identity project for people with cash, trackers and cold plunges. Increasingly, it is becoming a delivery model – one that blends prevention, digital access and long-term patient engagement. And if that future is to be meaningful, it cannot keep speaking only to the same audience.
Wisp’s bet is that women need care that actually fits their aging. In longevity, that’s the more durable innovation and the smarter business.
[1] https://www.businesswire.com/news/home/20260310550128/en/Wisp-Debuts-Women-Centric-Longevity-Suite-Via-New-Healthy-Aging-Vertical
[2] https://hellowisp.com/blog/closing-longevity-gap-for-women
